PMCK Berhad Announces Q3 FY2026 Results: Robust Financial Performance and Strategic Developments

Overview

PMCK Berhad, newly listed on the ACE Market of Bursa Malaysia Securities Berhad in July 2025, has released its unaudited interim financial report for the third quarter ended 31 January 2026. The report, reviewed by Malacca Securities Sdn. Bhd., presents a comprehensive update on the company’s financial health, operational progress, and forward-looking strategies, all of which are crucial for investors and shareholders.

Key Financial Highlights

• Revenue: For Q3 FY2026, PMCK Berhad recorded revenue of RM22.70 million. For the nine months ended 31 January 2026, revenue reached RM69.88 million. Healthcare support services remained the main revenue contributor, with inpatient care as the primary driver of patient care revenue.
• Profit Before Tax: Q3 FY2026 profit before tax was RM5.38 million. For the nine-month period, profit before tax was RM14.40 million. Notably, the period included a one-off listing expense of RM2.67 million, but this was offset by a net gain of RM6.06 million from the reversal of impairment of financial assets relating to previously undelivered COVID-19 vaccines.
• Net Profit: Q3 FY2026 net profit attributable to owners of the company was RM3.89 million, with a cumulative nine-month net profit of RM10.61 million.
• Earnings Per Share: Basic and diluted EPS stood at 0.36 sen for Q3 and 0.97 sen for the nine months ended 31 January 2026.
• Balance Sheet Strength: The company’s assets increased significantly, with total assets of RM205.55 million as at 31 January 2026 (up from RM122.69 million at 30 April 2025). Equity attributable to owners rose to RM157.71 million, reflecting the successful IPO and strong retained earnings. Net assets per share improved to RM0.14 (from RM0.11 at year-end).

Cash Flow and Financial Position

• Operating Cash Flow: Net cash from operating activities for the nine months was RM18.00 million, indicating solid cash generation.
• Investing Activities: Substantial investment outflows (RM82.38 million), driven by property, plant, and equipment acquisitions and placement of short-term investments.
• Financing Activities: Net cash from financing was RM65.73 million, primarily from IPO proceeds (RM57.94 million), new term loan drawdowns, and share issuance.
• Cash and Equivalents: Cash and bank balances at period-end stood at RM23.72 million.

Important Updates for Shareholders

• IPO and Share Issuance: PMCK Berhad completed its IPO, issuing 272.6 million new ordinary shares at RM0.22 per share and 32.7 million shares via offer for sale. The enlarged share capital is now 1,090,600,000 ordinary shares.
• Dividend: On 23 December 2025, a single-tier interim dividend of 0.12 sen per share (total RM1.31 million) was declared and paid on 28 January 2026.
• Utilisation of IPO Proceeds: Of the RM59.97 million raised, RM50 million is earmarked for repayment of bank borrowings for PMC Kulim, RM5.27 million for medical equipment acquisitions, and RM4.7 million for listing expenses (already utilised). The balance is yet to be utilised, with a 36-month timeframe.
• Borrowings: Total borrowings increased to RM32.32 million from RM22.10 million as at 30 April 2025, reflecting new term loan drawdowns to support expansion and investments.
• Capital Commitments: PMCK Berhad has authorised and contracted capital expenditure of RM163.55 million for land, buildings, and medical equipment, underscoring ongoing expansion and upgrades.
• Related Party Transactions: The report details RM1.80 million in specialist fees paid to key management and RM158,000 in laundry services provided by companies with director interests.

Operational and Strategic Developments

• Segmental Focus: PMCK Berhad operates predominantly in the provision of healthcare services. The management monitors the business as a single segment, with activities mainly in Malaysia.
• Q3 Performance vs. Previous Quarter: Revenue declined by RM2.72 million (10.7%) to RM22.70 million in Q3, and profit before tax dropped by RM2.40 million (30.81%) to RM5.38 million. The decline was attributed to reduced inpatient volumes and bed occupancy following the conclusion of the Ministry of Health’s Hospital Services Outsourcing Programme (HSOP) in December 2025. Increased administrative expenses, including nursing student sponsorships and legal/professional fees, also impacted profitability.
• Net Gain on Impairment Reversal: The quarter saw a significant net gain of RM3.02 million from the reversal of impairment of financial assets, due to full settlement received on undelivered COVID-19 vaccines.
• Forward-Looking Commentary: PMCK Berhad remains cautiously optimistic, supported by steady demand for private healthcare services. The group is actively recruiting additional specialists and upgrading medical equipment. Digital transformation initiatives, including improved electronic hospital information systems and patient appointment platforms, are underway to enhance patient experience and operational resilience.
• Industry Developments: The Ministry of Health’s ongoing data collection for the proposed Diagnosis-Related Group (DRG) framework could impact cost transparency and standardisation. PMCK Berhad is monitoring these developments for potential operational and financial implications.
• M&A Strategy: The group continues to evaluate selective merger and acquisition opportunities to complement existing operations, subject to strategic fit and financial discipline.

Risks and Price-Sensitive Items

• Contraction of Revenue: The end of the HSOP has led to lower inpatient volumes and reduced revenue, which could impact future profitability unless offset by other growth drivers.
• Capital Commitments: Large capital expenditure commitments (RM163.55 million) may affect future cash flows and require careful management.
• IPO Proceeds Utilisation: Investors should monitor the timely and effective use of IPO funds, especially for debt repayment and equipment upgrades.
• Taxation: The effective tax rate was higher than the statutory rate due to non-deductible expenses (including depreciation of non-qualifying assets and one-off listing expenses), impacting net profit margins.
• Dividend Policy: While an interim dividend was declared, the board did not recommend any further dividend for the current period, which may affect shareholder expectations.
• Material Events: No material events or litigation were reported post-period, but shareholders should remain alert to future developments.

Conclusion

PMCK Berhad’s Q3 FY2026 report reveals a solid financial foundation, successful IPO execution, and ongoing investments in expansion and technology. However, investors should note the revenue contraction following the conclusion of the HSOP, significant capital commitments, and the importance of ongoing operational enhancements. The group’s strategic focus on digital transformation, specialist recruitment, and potential M&A activity positions it for sustainable growth in Malaysia’s evolving private healthcare market.

Disclaimer

This article is based on PMCK Berhad’s unaudited interim financial report for Q3 FY2026 and is intended for informational purposes only. It does not constitute investment advice. Investors are advised to undertake their own due diligence and consult professional advisors before making investment decisions. The company’s performance and share price may be affected by future events and market conditions.

View PMCK BERHAD Historical chart here